Last updated 16 days ago

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

795 patients around the world
Available in Spain, Brazil, Argentina
Janssen Research & Development, LLC
9Research sites
795Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Británico de Buenos Aires - CABA
Hospital Británico de Buenos Aires - CABA
Recruiting
Perdriel 74, CABA, Buenos Aires
Hospital Alemán
Recruiting
Av. Pueyrredón 1640, CABA, Buenos Aires
Centro de Internación e Investigación Clínica FUNDALEU
Recruiting
J. E. Uriburu 1450, CABA, Buenos Aires
Hospital Erasto Gaertner
Recruiting
Rua Joaquim Amaral - Cajuru, Curitiba - PR, 81520, Brazil
Hospital de Clínicas de Porto Alegre
Recruiting
Santa Cecília, Porto Alegre - RS, 90450-190, Brazil
Hospital De Base de São José do Rio Preto - CIP São José
Recruiting
São José Do Rio Preto, São Paulo, 15090-000
Beneficência Portuguesa de São Paulo
Recruiting
R. Maestro Cardim, 637 - Bela Vista, São Paulo - SP, 01323-001
Hospitais Integradaos da Gavea - DF Star
Recruiting
SGAS I SGAS 914 - Asa Sul, Brasilia - Federal District, 70390-140
Fundação Universidade de Caxias do Sul
Recruiting
10 de febrero de 1967, Caxias do Sul, Río Grande del Sur
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy